Showing 20 of 80 recruiting trials for “Multiple myeloma”
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
👨⚕️ Jeffrey Zonder, M.D., Barbara Ann Karmanos Cancer Institute📍 2 sites📅 Started Dec 2023View details ↗
RecruitingNCT06463717 ↗
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
👨⚕️ Zhijuan Lin, The First Aiffiliated hosptical of xiamen University📍 1 site📅 Started Nov 2023View details ↗
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
👨⚕️ Peter A. Forsberg, MD, SCRI Development Innovations, LLC📍 17 sites📅 Started Oct 2023View details ↗
RecruitingNCT05879757 ↗
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecruitingNCT06082284 ↗
A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
RecruitingNCT05965115 ↗
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
👨⚕️ Enrique Ocio San Miguel, MD, PhD, Hospital Universitario Marqués de Valdecilla📍 11 sites📅 Started Jun 2023View details ↗
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →